Patients taking medications affecting the CYP3A4 pathway (ketoconazole, clarithromycin, erythromycin, rifampin, and protease inhibitors) were excluded from the ROCKET-AF trial due to potential drug-drug interactions [37]. The gene discussed is CYP3A4; the disease is atrial fibrillation.